News

Mar 21

2024

Phanes Therapeutics’ PT886 granted Fast Track designation for the treatment of patients with metastatic claudin 18.2-positive pancreatic adenocarcinoma by the FDA

SAN DIEGO, March 20, 2024 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and...
Read More

Jan 30

2024

Phanes Therapeutics, Inc. announces granting of registered trademarks for its three proprietary technology platforms by the U.S. Patent and Trademark Office

SAN DIEGO, Jan. 29, 2024 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and...
Read More

Oct 16

2023

Phanes Therapeutics, Inc. Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate PT886 in Combination with KEYTRUDA® (pembrolizumab)

PT886 is Phanes' first-in-class bispecific antibody targeting claudin 18.2 and CD47; KEYTRUDA® (pembrolizumab) is Merck's anti-PD-1 The clinical trial collaboration will...
Read More

Sep 14

2023

Phanes Therapeutics Announces the Appointment of Internationally Renowned Oncologist Prof. Shun Lu to its Clinical Advisory Board

SAN DIEGO, Sept. 14, 2023 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and...
Read More

Sep 7

2023

Phanes Therapeutics Announces First Patient Dosed in Phase 1 Study of PT217 for Small Cell Lung Cancer and Other Neuroendocrine Cancers Expressing DLL3

PT217 is a first-in-class bispecific antibody (bsAb) against human DLL3 (huDLL3) and human CD47 (huCD47) and is Phanes' third program...
Read More

Sep 5

2023

Phanes Therapeutics Announces the Establishment of Oncology Clinical Advisory Board

Distinguished, world renowned experts appointed to strengthen the development of Phanes' three clinical programs in oncology SAN DIEGO, Sept. 5, 2023 /PRNewswire/...
Read More

May 30

2023

Phanes Therapeutics announces the appointment of Rita Laeufle, MD, PhD, as Chief Medical Officer

SAN DIEGO, May 30, 2023 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and...
Read More

May 3

2023

GEN article: Bispecific Antibodies Expose Tumors to New Lines of Attack

Original link: Bispecific Antibodies Expose Tumors to New Lines of Attack (genengnews.com) By Amanda Heidt Ever since the first bispecific...
Read More

Mar 20

2023

Phanes Therapeutics Announces First Patient Dosed in Phase 1 Study of PT886 for Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinomas

SAN DIEGO, March 20, 2023 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and clinical development in...
Read More

Mar 6

2023

PHANES THERAPEUTICS entered into a research collaboration with Xyphos Biosciences, Inc., an Astellas Company

SAN DIEGO, March 6, 2023 /PRNewswire/ -- Phanes Therapeutics, Inc., a clinical stage biotech company focused on innovative drug discovery and development...
Read More
1 2 3 4